A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis

scientific article published on 30 November 2005

A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.2215/CJN.00120605
P698PubMed publication ID17699197

P2093author name stringAntonio Guasch
James A Tumlin
Randolph Hennigar
Danlyn Miller
Mitzi Near
Sasi Selvaraj
P433issue1
P921main subjectsirolimusQ32089
focal segmental glomerulosclerosisQ1435223
P304page(s)109-116
P577publication date2005-11-30
P1433published inClinical Journal of the American Society of NephrologyQ15757929
P1476titleA prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis
P478volume1

Reverse relations

cites work (P2860)
Q35056271Advances in the biology and genetics of the podocytopathies: implications for diagnosis and therapy
Q89838674Current understandings in treating children with steroid-resistant nephrotic syndrome
Q64106685Inhibiting 4E-BP1 re-activation represses podocyte cell cycle re-entry and apoptosis induced by adriamycin
Q41812610Inhibition of MTOR disrupts autophagic flux in podocytes
Q41787297Is There a Role for Mammalian Target of Rapamycin Inhibition in Renal Failure due to Mesangioproliferative Nephrotic Syndrome?
Q33571758Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study
Q37828086New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome
Q37218108Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors
Q57151742Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation
Q37760379Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases
Q37251705Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price?
Q53028092Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible?
Q38914374Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.
Q36674174Sirolimus-associated proteinuria and renal dysfunction
Q38922365Targeting mTOR Signaling Can Prevent the Progression of FSGS.
Q50210828The Akt/mTOR/p70S6K pathway is activated in IgA nephropathy and rapamycin may represent a viable treatment option
Q35614311Therapeutic approach to FSGS in children
Q26752836Treatment Strategies of Adult Primary Focal Segmental Glomerulosclerosis: A Systematic Review Focusing on the Last Two Decades
Q37218125mToR inhibitors-induced proteinuria: mechanisms, significance, and management

Search more.